Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
PLoS One. 2011;6(12):e27326. doi: 10.1371/journal.pone.0027326. Epub 2011 Dec 21.
The impact of pre-existing diabetes mellitus (DM) on hepatocellular carcinoma (HCC) occurrence and prognosis is complex and unclear. The aim of this meta-analysis is to evaluate the association between pre-existing diabetes mellitus and hepatocellular carcinoma occurrence and prognosis.
We searched PubMed, Embase and the Cochrane Library from their inception to January, 2011 for prospective epidemiological studies assessing the effect of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence, mortality outcomes, cancer recurrence, and treatment-related complications. Study-specific risk estimates were combined by using fixed effect or random effect models.
The database search generated a total of 28 prospective studies that met the inclusion criteria. Among these studies, 14 reported the risk of HCC incidence and 6 studies reported risk of HCC specific mortality. Six studies provided a total of 8 results for all-cause mortality in HCC patients. Four studies documented HCC recurrence risks and 2 studies reported risks for hepatic decomposition occurrence in HCC patients. Meta-analysis indicated that pre-existing diabetes mellitus (DM) was significantly associated with increased risk of HCC incidence [meta-relative risk (RR) = 1.87, 95% confidence interval (CI): 1.15-2.27] and HCC-specific mortality (meta-RR = 1.88, 95%CI: 1.39-2.55) compared with their non-DM counterparts. HCC patients with pre-existing DM had a 38% increased (95% CI: 1.13-1.48) risk of death from all-causes and 91% increased (95%CI: 1.41-2.57) risk of hepatic decomposition occurrence compared to those without DM. In DM patients, the meta-RR for HCC recurrence-free survival was 1.93(95%CI: 1.12-3.33) compared with non-diabetic patients.
The findings from the current meta-analysis suggest that DM may be both associated with elevated risks of both HCC incidence and mortality. Furthermore, HCC patients with pre-existing diabetes have a poorer prognosis relative to their non-diabetic counterparts.
糖尿病(DM)对肝癌(HCC)发生和预后的影响复杂且不明确。本荟萃分析旨在评估预先存在的糖尿病与肝细胞癌发生和预后的关系。
我们从建库至 2011 年 1 月在 PubMed、Embase 和 Cochrane Library 中检索前瞻性评估糖尿病对肝细胞癌发生、死亡率结局、癌症复发和治疗相关并发症影响的研究。采用固定或随机效应模型综合研究特异性风险估计。
数据库检索共产生了 28 项符合纳入标准的前瞻性研究。其中 14 项研究报告了 HCC 发生率的风险,6 项研究报告了 HCC 特异性死亡率的风险。6 项研究共提供了 8 项 HCC 患者全因死亡率的结果。4 项研究记录了 HCC 复发风险,2 项研究报告了 HCC 患者肝分解发生的风险。荟萃分析表明,与非糖尿病患者相比,糖尿病(DM)患者 HCC 发生率显著升高[汇总相对风险(RR)=1.87,95%置信区间(CI):1.15-2.27]和 HCC 特异性死亡率(汇总 RR=1.88,95%CI:1.39-2.55)。与无糖尿病患者相比,患有 DM 的 HCC 患者的全因死亡风险增加了 38%(95%CI:1.13-1.48),肝分解的发生风险增加了 91%(95%CI:1.41-2.57)。与非糖尿病患者相比,DM 患者的 HCC 无复发生存率的汇总 RR 为 1.93(95%CI:1.12-3.33)。
本荟萃分析的结果表明,DM 与 HCC 的发生和死亡率升高均相关。此外,与非糖尿病患者相比,患有预先存在的糖尿病的 HCC 患者预后更差。